Citalopram Safety Study Reveals Adverse Reactions: What You Need to Know

A recently conducted study by Northwind Pharmaceuticals, LLC shed light on the safety of the Citalopram tablet. The study included citalopram exposures in various groups, ranging from healthy subjects to patients with Major Depressive Disorder (MDD). It was found that adverse reactions associated with discontinuation of treatment were observed in a significant percentage of patients receiving Citalopram, compared to those on a placebo. The most common adverse reaction reported was ejaculation disorder in male patients. Furthermore, dose-dependent adverse reactions were noted, with a positive correlation between the dosage of Citalopram and the incidence of adverse reactions. Various other adverse reactions across different body systems were also identified during the premarketing evaluation of Citalopram, underscoring the importance of understanding potential side effects associated with this medication. This comprehensive study provides valuable insights into the safety profile of Citalopram and emphasizes the need for vigilant monitoring of patients undergoing treatment with this drug.